HomeInsightsPE

Syncom Formulations (india) Ltd PE Ratio

Syncom Formulations (india) Ltd PE Ratio

stocks purchased

₹ 1.9 Cr

Volume Transacted

(Dec 12, 2024)

stocks purchased

871.1 K

Stocks Traded

(Dec 12, 2024)

Last Updated on: Dec 13, 2024

Image

Syncom Formulations (India) Ltd

NSE: SYNCOMFORMUL

PE

62.2

Last updated on: Dec 13, 2024

Key Highlights

  • The P/E Ratio of Syncom Formulations (India) Ltd is 62.2 as of 13 Dec 9.00 AM .
  • The P/E Ratio of Syncom Formulations (India) Ltd changed from 46.2 on March 2022 to 41.4 on March 2024 . This represents a CAGR of -3.59% over 3 years.
  • The Latest Trading Price of Syncom Formulations (India) Ltd is ₹ 21.76 as of 12 Dec 15:30 .
  • The PE Ratio of Pharmaceuticals Industry has changed from 28.2 to 27.1 in 5 years. This represents a CAGR of -0.79%.
  • The PE Ratio of Automobile industry is 20.3. The PE Ratio of Finance industry is 17.8. The PE Ratio of IT - Software industry is 30.4. The PE Ratio of Pharmaceuticals industry is 40.0. The PE Ratio of Retail industry is 157.6. The PE Ratio of Textiles industry is 37.6 in 2024.

Historical P/E Ratio of Syncom Formulations (India) Ltd

No data available

Company Fundamentals for Syncom Formulations (India) Ltd

No data available

Image

Syncom Formulations (India) Ltd

NSE: SYNCOMFORMUL

Share Price

₹ 21.76

-0.80 (-3.55%)

stock direction

Last updated on: Dec 12, 2024

Market Price of Syncom Formulations (India) Ltd

1M

1Y

3Y

5Y

Monitoring Syncom Formulations (India) Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
12 Dec 202421.76
11 Dec 202422.56
10 Dec 202422.79
09 Dec 202423.62
06 Dec 202422.36
05 Dec 202422.27
04 Dec 202422.02
03 Dec 202422.06
02 Dec 202421.34
29 Nov 202420.11

SWOT Analysis Of Syncom Formulations (India) Ltd

Strength

3

S

Weakness

3

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Syncom Formulations (India) Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

Asset Value vs Market Value of Syncom Formulations (India) Ltd

Market Value

0

Asset Value

0

* All values are in Rupees

Competitive Comparison of P/E Ratio

Key Valuation Metric of Syncom Formulations (India) Ltd

No data available

No data available

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Historical Market Cap of Syncom Formulations (India) Ltd

No data available

* All values are in crore

Historical Revenue of Syncom Formulations (India) Ltd

No data available

* All values are in crore

Historical EBITDA of Syncom Formulations (India) Ltd

No data available

* All values are in crore

Historical Net Profit of Syncom Formulations (India) Ltd

No data available

* All values are in crore

Historical Dividend Payout of Syncom Formulations (India) Ltd

No data available

* All values are in %

About Syncom Formulations (India) Ltd

  • Incorporated as a private limited company in 1988, Syncom Formulations (India) Limited was converted into a public limited company in Jun.'92.
  • The Company in the Indian Pharmaceutical Industry represents synergistic combination of commitment and consistency.
  • Syncom possesses the manufacturing strength in its own manufacturing set-up at Pithampur, Madhya Pradesh. Established in 1988, Syncom plant is geared up with latest production machineries and maintains high quality standards.
  • Currently, the Company manufactures and markets more than 200 pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers. The company set up a manufacturing facility at Palghar, Thane to produce pharmaceutical formulations.

Syncom Formulations (India) Ltd News Hub

News

Nifty slips below 24,200 level; Nifty bank shares buck trend; HDFC Bank drops 2.93%

The main equity indices traded with significant losses in mid-afternoon trade. The Nifty d...

Read more

2024-08-13 00:00:00

News

Syncom Formulations gains after Q1 PAT rises over 73% YoY

Net sales rose by 45.8% year-over-year (YoY) during the quarter to Rs 87.26 crore. Total e...

Read more

2024-08-13 00:00:00

News

Syncom Formulations (India) consolidated net profit rises 73.41% in the June 2024 quarter

Net profit of Syncom Formulations (India) rose 73.41% to Rs 7.63 crore in the quarter ende...

Read more

2024-08-12 00:00:00

News

Syncom Formulations (India) announces board meeting date

Syncom Formulations (India) will hold a meeting of the Board of Directors of the Company o...

Read more

2024-08-06 00:00:00

Product Composition

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQs for PE of Syncom Formulations (India) Ltd

What is the current PE Ratio of Syncom Formulations (India) Ltd?

The Current PE Ratio of Syncom Formulations (India) Ltd is 62.17 as on 13 Dec 2024.

What is the average PE Ratio of the Pharmaceuticals industry?

The average industry PE Ratio of Pharmaceuticals is 40.0 as on 13 Dec 2024.

What was the PE Ratio of Syncom Formulations (India) Ltd last year?

The PE Ratio of Syncom Formulations (India) Ltd was 28.1 last year, now the PE ratio is 62.17, showing a year-on-year growth of 121.2%.

What does the PE Ratio of Syncom Formulations (India) Ltd indicate about its stock?

The PE Ratio of Syncom Formulations (India) Ltd is 62.17. This ratio indicates that investors are willing to pay 62.17 times the earnings per share for each share of Syncom Formulations (India) Ltd.

What is the PE Ratio Growth of Syncom Formulations (India) Ltd in comparison to its Earnings per Share (EPS) growth rate?

The PE Ratio of Syncom Formulations (India) Ltd grew by 121.2% whereas, the EPS ratio grew by 45.5.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Demat Account
Verify your phone
+91
*By signing up you agree to our terms & conditions